<- Back to digest

JOT - 2026-11-01 - Journal Article

Single Antibiotic Use With Ceftriaxone for Prophylaxis of All Open Fractures.

Koulopoulos MW, Buseck A, Lynch CP, Lutz K, Brand O, Sommers E, Pompo I, Laychur A, Vaughn J, Mann K, Sullivan MP

retrospective cohortLOE IIIn = 521Minimum 3 months.

Topics

trauma
PMID: 42200576DOI: 10.1097/BOT.0000000000003229View on PubMed ->

Key Takeaway

Ceftriaxone monotherapy for all open fractures demonstrated noninferiority to the classic cefazolin-based protocol for deep infection (7.8% vs. 12.7%) and reduced time to antibiotic administration by 50 minutes (63.9 vs. 114.1 minutes).

Summary Depth

Choose how much analysis to show on this article page.

Summary

This study compared ceftriaxone monotherapy for all open fractures against a classic protocol (cefazolin for Gustilo I/II; cefazolin plus gentamicin or ceftriaxone for Gustilo III) at a single Level I trauma center from 2016–2022. Deep infection rates did not differ significantly (7.8% vs. 12.7%, P=0.095), and noninferiority of ceftriaxone was formally demonstrated for all Gustilo types (intergroup difference -0.048, P=0.027) and type I/II fractures (-0.054, P=0.035). The ceftriaxone protocol reduced time to antibiotic administration by approximately 50 minutes (63.9 vs. 114.1 minutes, P=0.002).

Key Limitation

The study is underpowered to detect a true difference in deep infection rates, meaning noninferiority cannot be interpreted as equivalence with confidence, especially for high-risk Gustilo IIIB/IIIC fractures.

Original Abstract

OBJECTIVES

To compare outcomes for open fractures treated with a prophylactic antibiotic protocol using ceftriaxone (CTX) for all open fractures, referred to as group "CTX," versus a previous protocol using cefazolin for Gustilo I/II fractures and cefazolin plus gentamicin or CTX monotherapy for Gustilo type III fractures only, referred to as group "Classic."

DESIGN

Retrospective cohort study.

SETTING

Single level I trauma center.

PATIENT SELECTION CRITERIA

This study included adult patients undergoing surgery for an open fracture from December 2016 to December 2022 with a minimum follow-up of 3 months.

OUTCOME MEASURES AND COMPARISONS

The primary outcome of deep infection and secondary outcomes of superficial infection rates, nonunion rate, and time to antibiotic administration were compared between overall groups and subgroups based on Gustilo type.

RESULTS

A total of 521 patients were included. Baseline characteristics were similar between groups, with no differences in age (CTX 41.1 ± 19.7 vs. classic 39.5 ± 19.3), sex (68.5% vs. 72.0% male), or comorbidities ( P > 0.05). There were no differences in deep infection (7.8% vs. 12.7%, P = 0.095), superficial infection (7.0% vs. 4.7%, P = 0.427), or nonunion (10.3% vs. 7.9%, P = 0.500) between CTX and Classic groups for all Gustilo types. Similarly for only type I/II fractures, rates of deep infection (3.5% vs. 8.9%, P = 0.145), superficial infection (2.9% vs. 3.6%, P = 0.683), and nonunion (3.6% vs. 0.0%, P = 0.340) did not differ. Noninferiority of CTX for deep infection was demonstrated for all Gustilo types (intergroup difference -0.048, P = 0.027) and type I/II fractures (-0.054, P = 0.035). The CTX protocol was associated with shorter time to antibiotic administration (63.9 ± 116.9 vs. 114.1 ± 199.0 minutes, P = 0.002).

CONCLUSIONS

The use of CTX for prophylaxis of all open fractures, regardless of Gustilo type, was associated with noninferior outcomes in deep infection as well as shorter time to antibiotic administration, compared with a regimen where type I/II fractures received cefazolin. No significant differences in rates of superficial infection or nonunion were noted after transition to CTX protocol. The study was notably underpowered to detect a difference in the primary outcome of deep infection. Prophylaxis of all open fractures with CTX may be a safe and effective method of standardizing and expediting care for orthopaedic trauma patients.

LEVEL OF EVIDENCE

Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.